Ionis and Otsuka score EU nod for DAWNZERA, offering new hope for rare HAE patients

The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe

AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder

Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector

China nod to two Sanofi drugs for rare and complex conditions

Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

Avista Therapeutics unveils AI-powered expansion of gene therapy platform

The company is rolling out ARTEMIS, a next-generation AI platform for capsid design

FDA nod to first-ever treatment for fatal pediatric Menkes disease

Metropolis Healthcare launches Genomics Centre to scale precision diagnostics and research

Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases

Arrowhead Pharmaceuticals gets green light for first-of-its-kind FCS therapy

REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS

Dr. Lal PathLabs launches tech-driven personalized wellness center 'Sovaaka'

Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks

Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance

The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026